Description
Abemaciclib is a CDK4 and CDK6 inhibitor found to inhibit retinoblastoma phosphorylation, leading to G1/S arrest in ER+ breast cancer cells and to promote metabolic alterations in metastatic HR+ breast cancer cells.
Abemaciclib mesylate
Product ID A044178
Cas No. 1231930-82-7
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1231930-82-7 |
|---|---|
| Purity | ≥98% |
| Formula | C27H32F2N8 • CH4O3S |
| Formula Wt. | 602.71 |
| Chemical Name | N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine methanesulfonate |
| Synonym | LY2835219 methanesulfonate |
| Solubility | DMSO:84 mg/mL; Water:100 mg/mL |
| Appearance | White powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Blue Ice |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Torres-Guzman R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget. 2017 May 10. Epub ahead of print. PMID: 28537883
Tate SC, Burke TF, Hartman D, et al. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. Br J Cancer. 2016 Mar 15;114(6):669-679. PMID: 26978007
Knudsen ES, Hutcheson J, Vail P, et al. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jun 10. Epub ahead of print. PMID: 28620137